Andrew Hopkins, Exscientia CEO (Exscientia)
April 9, 2021 10:59 AM EDTUpdated 04:48 PM
R&D
AI

Lay­ing claim to an­oth­er AI 'first,' Ex­sci­en­tia tees up an I/O drug for the clin­ic

Josh Sullivan

In Jan­u­ary 2020, Ex­sci­en­tia an­nounced that a drug mol­e­cule to treat OCD in­vent­ed by AI was set to en­ter clin­i­cal tri­als for the first time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times